IMBiologics

로고

언어선택 ENG

전체메뉴

History

Innovative Medicines based on
ImmunoModulatory Biologics

2024

02: Signing a joint research agreement with Dong-A ST using ePENDY platform technology
01: Patent registration of ePENDY platform technology in Korea

2023

12: IMB-101, Selection of the top 10 excellent projects for KDDF 2023
11: IMB-101, American College of Rheumatology (ACR) 2023 conference poster
10: MOU with China Canton Biologics: Strategic collaboration agreement based on ePENDY platform technology
07: Completion of 20 Bil. KRW Series B Funding
07: IMB-101 : US FDA IND approval
07: IMB-101, Antibody Society Korea (ASK) 2023 conference presentation
06: IMB-101 : US FDA IND submission
04: ePENDY Platform : poster presentation at American Cancer Society (AACR)

2022

12: IMB-101 : Nature biopharma dealmakers printed/online
11: MOU with Dong-A ST: research based on ePENDY platform technology
07: ePENDY Platform, Antibody Society Korea (ASK) 2022 conference presentation
03: IMB-101 project funded by KDDF(Korea Drug Development Fund)
03: The 2nd annual shareholder meeting

2021

08: Completion of 13 Bil. KRW Series A Funding by KB, Atinum, Partners, IMM and Timewise investment firms
04: Completion of the trademark application
03: Approval of the LMO facility
03: The 1st annual shareholder meeting
02: Certification of the venture company
01: Completion of 4 Bil. KRW Seed Funding led by KB investment and Atinum investment

2020

12: Certification of the company-affiliated research institute
11: Relocation of the HQ and the research institute to Gwanggyo Central Biz Tower
11: Worldwide exclusive in-licensing agreement for OXTIMA(IMB-101) with HK inno.N
10: Patent application for the IMB platform technology
09: Temporary research institute established at Gyeonggi Bio Center
08: Establishment of IMBiologics Inc.